Moleculin Biotech (NASDAQ: MBRX) to Begin Preparing Clinical Testing Sites for Leukemia Treatment
NASDAQ Biotechnology Index up and climbing Developing new treatment for acute myeloid leukemia (AML) Lead candidate, Annamycin, now at phase II Since a rising sea lifts all boats, it’s decidedly good news for Moleculin Biotech, Inc. (NASDAQ: MBRX) that the NASDAQ Biotechnology Index (NBI) is enjoying a spring tide. The index has offered a year-to-date return of over 17 percent and seems set to keep climbing. This benign environment gives Moleculin an opportunity to advance work on its leading anti-cancer drug candidates. The company has begun to identify and prepare testing sites in Europe and has already appointed a Lead…